跳至主要内容
临床试验/NCT05461599
NCT05461599终止不适用

Feasibility and Acceptability of a Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology

Limbix Health, Inc.2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2022年8月25日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
2
试验地点
2
主要终点
Feasibility of intervention - Eligibility

研究概览

简要总结

The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of depression among adolescents being treated in specialty medical care settings at Children's Hospital of Los Angeles (CHLA).

详细描述

Self-report assessments will be collected at pre, post and 1-month follow up time points. Weekly PHQ-8 assessments will also be collected during the 5-week intervention as well as at pre, post and 1- month follow up time points.

Study aims involve evaluating:

  • Feasibility of recruiting and enrolling adolescents with elevated symptoms of depression from the Cardiology and Gastroenterology programs at CHLA.
  • Retention, program adherence, completion, and withdrawal rates.
  • Safety of the intervention, including reported adverse and serious adverse events
  • Perceived utility, usability, and enjoyment of the SparkRx app by adolescents
  • Clinically significant changes in pre- to -post treatment depressive symptoms and persistence of such gains at 1 month follow up.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
13 Years 至 22 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 13-22 years of age at time of enrollment
  • Moderate-severe self-reported symptoms of depression at baseline (PHQ-8 >=5)
  • Under the care of a US-based healthcare provider and willing and able to provide the name and contact information of the provider during consent
  • English fluency or proficiency and literacy of adolescent and consenting legal guardian, if required
  • Access to an eligible mobile device (capable of installing the app) and regular internet access
  • Willing to provide informed e-consent/assent and have legal guardian willing to provide informed e consent (if required)

排除标准

  • Change in concurrent treatment (medication, and/or psychotherapy) for depression 30 days prior to study enrollment
  • Suicide attempt within the past year
  • Active suicide ideation with intent
  • Previously participated in user testing or clinical testing of the Spark app
  • Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the treatment (e.g., unable to perform informed assent or consent, treatment resistance as determined by investigator) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)

结局指标

主要结局

Feasibility of intervention - Eligibility

时间窗: Screening

Percent of potential participants eligible to participate

Feasibility of intervention - Participant willingness

时间窗: Screening

Percent of eligible participants willing to participate

Participant satisfaction with the SparkRx app

时间窗: 5 weeks

Acceptability of intervention. Measured by the User Experience (UXR) questionnaire. Includes questions from the UMUX-Lite; a two-item questionnaire that assesses the usability of the mobile application. Questions have seven response options from Strongly agree to Strongly disagree. Includes questions from the HaTs questionnaire; an open-ended questionnaire that assesses respondents' experiences with the product and provides options for feedback.

Feasibility of intervention - Adherence

时间窗: 5 weeks

Adherence to program: percent of enrolled participants completing all modules by post-treatment

次要结局

  • Change in legal-guardian reported health-related quality of life(Change from screening to post-intervention (5 weeks))
  • Change in participant-reported health-related quality of life(Change from screening to post-intervention (5 weeks))
  • Change in participant-rated anxiety symptoms(Change from screening to post-intervention (5 weeks))
  • Average treatment related engagement rating(5 weeks)
  • Average treatment related program adherence(5 weeks)
  • Change in legal guardian-reported depressive symptoms(Change from screening to post-intervention (5 weeks))
  • Average treatment related program engagement(5 weeks)
  • Change in depressive symptoms(Change from screening to post-intervention (5 weeks))
  • Average treatment related usability rating(5 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验